

C O M P A N Y O V E R V I E W

Boston Scientific (NYSE: BSX) is a worldwide developer, manufacturer and marketer of medical devices with approximately 25,000 employees and revenue of \$8.188 billion in 2009. For more than 30 years, Boston Scientific has advanced the practice of less-invasive medicine¹ by providing a broad and deep portfolio of innovative products, technologies and services across a wide range of medical specialties. The Company's products help physicians and other medical professionals improve their patients' quality of life by providing alternatives to surgery. For more information, please visit www.bostonscientific.com.

MISSION

Boston Scientific's mission is to improve the quality of patient care and the productivity of health care delivery through the development and advocacy of less-invasive medical devices and procedures. This is accomplished through the continuing refinement of existing products and procedures and the investigation and development of new technologies which can reduce risk, trauma, cost, procedure time and the need for aftercare.

HISTORY

Boston Scientific's history began in the late 1960s, when co-founder John Abele acquired an equity interest in Medi-tech, Inc., a research and development company focused on developing alternatives to traditional surgery. Medi-tech's first products, a family of steerable catheters, were introduced in 1969 and were used in some of the first less-invasive procedures. Versions of these steerable catheters are still used today. In 1979, Abele and Pete Nicholas partnered to buy Medi-tech and together formed Boston Scientific Corporation.

¹ Less-invasive medical technologies provide alternatives to major surgery and other medical procedures that are typically traumatic to the body. In less-invasive procedures, devices are usually inserted into the body through natural openings or small incisions and can be guided to most areas of the anatomy to diagnose and treat a wide range of medical problems.

Fact Sheet
Page 2 of 3

FINANCIAL INFORMATION

2009 Revenue: \$8.188 billion

Stock Exchange: NYSE, Symbol: BSX

BUSINESSES

- Cardiology, Rhythm and Vascular Group
 - Endovascular Unit
 - Peripheral Interventions
 - Neurovascular
 - Imaging
 - Electrophysiology
- Endoscopy Division
- Urology and Women's Health Division
- Neuromodulation Division

HEADQUARTERS

Corporate:


One Boston Scientific Place
Natick, MA 01760-1537
United States
(508) 650-8000
www.bostonscientific.com

Regional:

- Boston Scientific International S.A.
Paris
- Boston Scientific Japan K.K.
Tokyo

EXECUTIVE COMMITTEE

- J. Raymond Elliott – President and Chief Executive Officer
- Brian R. Burns – Executive Vice President, Global Quality and Regulatory Affairs
- Jeffrey D. Capello – Executive Vice President, Chief Financial Officer
- Keith D. Dawkins, M.D. – Senior Vice President, Chief Medical Officer, Cardiology, Rhythm and Vascular Group
- Joe M. Fitzgerald – Senior Vice President, Endovascular Unit
- William H. (Hank) Kucheman – Executive Vice President and President, Cardiology, Rhythm & Vascular Group
- Jean Fitterer Lance – Senior Vice President and Chief Compliance Officer
- Samuel R. Leno – Executive Vice President and Chief Operations Officer
- Stephen F. Moreci – Senior Vice President, Global Sales Operations
- J. Michael Onuscheck – Senior Vice President and President, Neuromodulation Division
- John B. Pedersen – Senior Vice President and President, Urology and Women's Health Division
- Michael P. Phalen – Senior Vice President, Endoscopy Division



Fact Sheet
Page 3 of 3

- Tim Pratt – Executive Vice President, Chief Administrative Officer, General Counsel and Secretary
- Ken Pucel – Executive Vice President, Operations

ANNUAL REPORT

Boston Scientific's 2009 Annual Report is available to download at www.bostonscientific.com.

CONTACT INFORMATION

For more information, please contact Paul Donovan, Senior Vice President of Corporate Communications, at (508) 650-8541 or visit our web site at www.bostonscientific.com.